Literature DB >> 15876932

Pertussis immunization of adolescents in the United States: an economic evaluation.

J Jaime Caro1, Denis Getsios, Wissam El-Hadi, Krista Payne, Judith A O'Brien.   

Abstract

The incidence of reported pertussis has increased during the past decade and poses a growing health and economic burden in developed countries, despite high rates of primary vaccination. Administration of a booster dose of acellular pertussis vaccine to adolescents may help reduce this burden, not only by reducing infections in vaccinated individuals but also by reducing transmission of Bordetella pertussis to other individuals, particularly infants. An epidemiologic model was created to assess the health and economic impact of implementing a program of routine acellular pertussis immunization in adolescents 11-18 years of age in the United States, considering both the reduction in cases in those vaccinated and among the unvaccinated population (due to herd immunity). Inputs for the base case were defined according to information derived from published literature and were supplemented by estimates provided by members of the Global Pertussis Initiative. Both direct and indirect costs were included (in 2002 US dollars) using U.S. data. Outcomes were evaluated over the lifetime of a cohort of potential adolescent vaccine candidates. Because of uncertainty in many of the inputs, extensive sensitivity analyses were conducted. With 80% vaccination coverage of adolescents and a 20% reduction of other cases because of herd immunity, >68,000 cases and 41 pertussis-related deaths would be avoided in the subsequent 10 years by routine administration of acellular pertussis boosters to a single cohort of adolescents in the United States. This strategy would be cost-effective, incurring from 6000 US dollars to 22,000 US dollars per life-year gained. The level of herd immunity attained and the true incidence of pertussis are critical determinants of cost effectiveness, as is the duration of immunity resulting from immunization. The cost of immunization and the discount rate also play a role. Although there is considerable uncertainty surrounding key inputs, the results indicate that the conditions required for adolescent immunization to be economically warranted are realistic.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15876932     DOI: 10.1097/01.inf.0000160918.72953.51

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  14 in total

1.  Adult pertussis vaccination strategies and their impact on pertussis in the United States: evaluation of routine and targeted (cocoon) strategies.

Authors:  L Coudeville; A van Rie; P Andre
Journal:  Epidemiol Infect       Date:  2007-07-05       Impact factor: 2.451

2.  Development, theoretical framework, and evaluation of a parent and teacher-delivered intervention on adolescent vaccination.

Authors:  Lisa M Gargano; Natasha L Herbert; Julia E Painter; Jessica M Sales; Tara M Vogt; Christopher Morfaw; LaDawna M Jones; Dennis Murray; Ralph J DiClemente; James M Hughes
Journal:  Health Promot Pract       Date:  2014-01-17

Review 3.  Novel therapies for the treatment of pertussis disease.

Authors:  Karen M Scanlon; Ciaran Skerry; Nicholas H Carbonetti
Journal:  Pathog Dis       Date:  2015-09-21       Impact factor: 3.166

Review 4.  Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2012-09-10       Impact factor: 9.546

5.  Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model.

Authors:  Robin de Vries; Mirjam Kretzschmar; Joop F P Schellekens; Florens G A Versteegh; Tjalke A Westra; John J Roord; Maarten J Postma
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

6.  Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly.

Authors:  Lisa J McGarry; Girishanthy Krishnarajah; Gregory Hill; Michelle Skornicki; Narin Pruttivarasin; Cristina Masseria; Bhakti Arondekar; Stephen I Pelton; Milton C Weinstein
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

7.  Improving adherence rates to a cocooning program: a pilot experience in Italy.

Authors:  Andrea Simonetti; Ida Martini; Gennaro Bonomo; Raffaele D'Avino; Paolo Puggina; Ugo Vairo; Pasquale Piscopo; Federico Marchetti
Journal:  Hum Vaccin Immunother       Date:  2013-01-31       Impact factor: 3.452

8.  Cost-effectiveness of Tdap vaccination of adults aged ≥65 years in the prevention of pertussis in the US: a dynamic model of disease transmission.

Authors:  Lisa J McGarry; Girishanthy Krishnarajah; Gregory Hill; Cristina Masseria; Michelle Skornicki; Narin Pruttivarasin; Bhakti Arondekar; Julie Roiz; Stephen I Pelton; Milton C Weinstein
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

9.  Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects.

Authors:  Laurent Coudeville; Annelies Van Rie; Denis Getsios; J Jaime Caro; Pascal Crépey; Van Hung Nguyen
Journal:  PLoS One       Date:  2009-07-16       Impact factor: 3.240

10.  Whooping cough in school age children presenting with persistent cough in UK primary care after introduction of the preschool pertussis booster vaccination: prospective cohort study.

Authors:  Kay Wang; Norman K Fry; Helen Campbell; Gayatri Amirthalingam; Timothy G Harrison; David Mant; Anthony Harnden
Journal:  BMJ       Date:  2014-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.